Inactivated mesenchymal stem cells maintain immunomodulatory capacity

Stem Cells and Development

Volumn 25, Issue 18, 2016, Pages 1342-1354

  Luk, Franka ^a   De Witte, Samantha F H ^a   Korevaar, Sander S ^a   Roemeling Van Rhijn, Marieke ^b   Franquesa, Marcella ^a   Strini, Tanja ^a   Van Den Engel, Sandra ^a   Gargesha, Madhusudhana ^c   Roy, Debashish ^c   Dor, Frank J M F ^a   Horwitz, Edwin M ^d   De Bruin, Ron W F ^a   Betjes, Michiel G H ^a   Baan, Carla C ^a   Hoogduijn, Martin J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c BIOINVISION INC   (United States)

^d NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; CD31 ANTIGEN; CD45 ANTIGEN; CXCL1 CHEMOKINE; ENDOGLIN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MICROSOMAL AMINOPEPTIDASE; MONOCYTE CHEMOTACTIC PROTEIN 1; THY 1 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; VASCULOTROPIN; CYTOKINE; LIPOPOLYSACCHARIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL ACTIVATION; CELL FUNCTION; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; HEAT; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPHENOTYPING; IN VITRO STUDY; INFLAMMATION; KIDNEY INJURY; KIDNEY PARENCHYMA; LIPOPOLYSACCHARIDE-INDUCED SEPSIS; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STEM CELL; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS FAT; T LYMPHOCYTE; THERMAL EXPOSURE; ANIMAL; C57BL MOUSE; CELL MOTION; CELL PROLIFERATION; CYTOLOGY; DISEASE MODEL; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MALE; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; SEPSIS; TISSUE DISTRIBUTION;

ANIMALS; B-LYMPHOCYTES; CELL MOVEMENT; CELL PROLIFERATION; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOMODULATION; IMMUNOPHENOTYPING; INFLAMMATION; INFUSIONS, INTRAVENOUS; LIPOPOLYSACCHARIDES; MALE; MESENCHYMAL STROMAL CELLS; MICE, INBRED C57BL; MONOCYTES; SEPSIS; T-LYMPHOCYTES; TISSUE DISTRIBUTION;

EID: 84987749772     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2016.0068     Document Type: Article

References (45)

1. Pittenger MF, A.M. Mackay, S.C. Beck, R.K. Jaiswal, R. Douglas, J.D. Mosca, M.A. Moorman, D.W. Simonetti, S. Craig, and D.R. Marshak. (1999). Multilineage potential of adult human mesenchymal stem cells. Science 284:143-147
2. Gonzalez MA, E. Gonzalez-Rey, L. Rico, D. Buscher, and M. Delgado. (2009). Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory, and autoimmune responses. Gastroenterology 136:978-989
3. Constantin G, S. Marconi, B. Rossi, S. Angiari, L. Calderan, E. Anghileri, B. Gini, S.D. Bach, M. Martinello, et al. (2009). Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells 27:2624-2635
4. Popp FC, E. Eggenhofer, P. Renner, P. Slowik, S.A. Lang, H. Kaspar, E.K. Geissler, P. Piso, H.J. Schlitt, and M.H. Dahlke. (2008). Mesenchymal stem cells can induce long-Term acceptance of solid organ allografts in synergy with low-dose mycophenolate. Transpl Immunol 20:55-60
5. Roemeling-van Rhijn M, M. Khairoun, S.S. Korevaar, E. Lievers, D.G. Leuning, J.N. Ijzermans, M.G. Betjes, P.G. Genever, C van Kooten, et al. (2013). Human bone marrow-, and adipose tissue-derived mesenchymal stromal cells are immunosuppressive, and in a humanized allograft rejection model. J Stem Cell Res Ther Suppl 6:20780
6. Gonzalez-Rey E, P. Anderson, M.A. Gonzalez, L. Rico, D. Buscher, and M. Delgado. (2009). Human adult stem cells derived from adipose tissue protect against experimental colitis, and sepsis. Gut 58:929-939
7. Augello A, R. Tasso, S.M. Negrini, R. Cancedda, and G. Pennesi. (2007). Cell therapy using allogeneic bone marrow mesenchymal stemcells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum 56:1175-1186
8. Tobin LM, M.E. Healy, K. English, and B.P. Mahon. (2013). Human mesenchymal stem cells suppress donor CD4(+) T cell proliferation, and reduce pathology in a humanized mouse model of acute graft-versus-host disease. Clin Exp Immunol 172:333-348
9. Joo SY, K.A. Cho, Y.J. Jung, H.S. Kim, S.Y. Park, Y.B. Choi, K.M. Hong, S.Y. Woo, J.Y. Seoh, S.J. Cho, and K.H. Ryu. (2010). Mesenchymal stromal cells inhibit graft-versus-host disease of mice in a dose-dependent manner. Cytotherapy 12:361-370
10. Le Blanc K, F. Frassoni, L. Ball, F. Locatelli, H. Roelofs, I. Lewis, E. Lanino, B. Sundberg, M.E. Bernardo, et al. (2008). Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371:1579-1586
11. Bernardo ME, L.M. Ball, A.M. Cometa, H. Roelofs, M. Zecca, M.A. Avanzini, A. Bertaina, L. Vinti, A. Lankester, et al. (2011). Co-infusion of ex vivo-expanded, parental MSCs prevents life-Threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone Marrow Transplant 46:200-207
12. Hu J, X. Yu, Z. Wang, F. Wang, L. Wang, H. Gao, Y. Chen, W. Zhao, Z. Jia, S. Yan, and Y. Wang. (2013). Long term effects of the implantation of Wharton s jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus. Endocr J 60:347-357
13. Forbes GM, M.J. Sturm, R.W. Leong, M.P. Sparrow, D. Segarajasingam, A.G. Cummins, M. Phillips, and R.P. Herrmann. (2014). A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn s disease refractory to biologic therapy. Clin Gastroenterol Hepatol 12:64-71
14. Wang D, H. Zhang, J. Liang, X. Li, X. Feng, H. Wang, B. Hua, B. Liu, L. Lu, et al. (2013). Allogeneic mesenchymal stem cell transplantation in severe, and refractory systemic lupus erythematosus: 4 years of experience. Cell Transplant 22:2267-2277
15. Franquesa M, M.J. Hoogduijn, M.E. Reinders, E. Eggenhofer, A.U. Engela, F.K. Mensah, J. Torras, A. Pileggi, C van Kooten, et al. (2013). Mesenchymal stem cells in solid organ transplantation (MiSOT) fourth meeting: lessons learned from first clinical trials. Transplantation 96:234-238
16. Luk F, SF de Witte, W.M. Bramer, C.C. Baan, and M.J. Hoogduijn. (2015). Efficacy of immunotherapy with mesenchymal stem cells in man: a systematic review. Expert Rev Clin Immunol 11:617-636
17. Munneke JM, M.J. Spruit, A.S. Cornelissen, V van Hoeven, C. Voermans, and M.D. Hazenberg. (2015). The potential of mesenchymal stromal cells as treatment for severe steroidrefractory acute graft-versus-host disease: a critical review of the literature. Transplantation [Epub ahead of print]; DOI: 10.1097/TP.0000000000001029
18. Jin SZ, B.R. Liu, J. Xu, F.L. Gao, Z.J. Hu, X.H. Wang, F.H. Pei, Y. Hong, H.Y. Hu, and M.Z. Han. (2012). Ex vivo-expanded bone marrow stem cells home to the liver, and ameliorate functional recovery in a mouse model of acute hepatic injury. Hepatobiliary Pancreat Dis Int 11:66-73
19. Assis AC, J.L. Carvalho, B.A. Jacoby, R.L. Ferreira, P. Castanheira, S.O. Diniz, V.N. Cardoso, A.M. Goes, and A.J. Ferreira. (2010). Time-dependent migration of systemically delivered bone marrow mesenchymal stem cells to the infarcted heart. Cell Transplant 19:219-230
20. Barbash IM, P. Chouraqui, J. Baron, M.S. Feinberg, S. Etzion, A. Tessone, L. Miller, E. Guetta, D. Zipori, L.H. Kedes, R.A. Kloner, and J. Leor. (2003). Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation 108:863-868
21. Eggenhofer E, F. Luk, M.H. Dahlke, and M.J. Hoogduijn. (2014). The life, and fate of mesenchymal stem cells. Front Immunol 5:148
22. Waterman RS, S.L. Tomchuck, S.L. Henkle, and A.M. Betancourt. (2010). A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS One 5:e10088
23. Di Nicola M, C. Carlo-Stella, M. Magni, M. Milanesi, P.D. Longoni, P. Matteucci, S. Grisanti, and A.M. Gianni. (2002). Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99:3838-3843
24. Groh ME, B. Maitra, E. Szekely, and O.N. Koc. (2005). Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. ExpHematol 33:928-934
25. Spaggiari GM, A. Capobianco, H. Abdelrazik, F. Becchetti, M.C. Mingari, and L. Moretta. (2008). Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2, 3-dioxygenase, and prostaglandin E2. Blood 111:1327-1333
26. Hsu WT, C.H. Lin, B.L. Chiang, H.Y. Jui, K.K. Wu, and C.M. Lee. (2013). Prostaglandin E2 potentiates mesenchymal stem cellinduced IL-10+IFN-gamma+CD4+ regulatory T cells to control transplant arteriosclerosis. J Immunol 190:2372-2380
27. Liang C, S.L. Chen, M. Wang, W.J. Zhai, Z. Zhou, A.M. Pang, S.Z. Feng, and M.Z. Han. (2013). [Synergistic immunomodulatory effects of interferon-gamma, and bone marrow mesenchymal stem cells]. Zhonghua Xue Ye Xue Za Zhi 34:213-216
28. Gu YZ, Q. Xue, Y.J. Chen, G.H. Yu, M.D. Qing, Y. Shen, M.Y. Wang, Q. Shi, and X.G. Zhang. (2013). Different roles of PD-L1, and FasL in immunomodulationmediated by human placentaderived mesenchymal stemcells. HumImmunol 74:267-276
29. Luz-Crawford P, D. Noel, X. Fernandez, M. Khoury, F. Figueroa, F. Carrion, C. Jorgensen, and F. Djouad. (2012). Mesenchymal stem cells repress Th17 molecular program through the PD-1 pathway. PLoS One 7:e45272
30. Caplan AI, and D. Correa. (2011). The MSC: an injury drugstore. Cell Stem Cell 9:11-15
31. Eggenhofer E, V. Benseler, A. Kroemer, F.C. Popp, E.K. Geissler, H.J. Schlitt, C.C. Baan, M.H. Dahlke, and M.J. Hoogduijn. (2012). Mesenchymal stem cells are short-lived, and do not migrate beyond the lungs after intravenous infusion. Front Immunol 3:297
32. Schrepfer S, T. Deuse, H. Reichenspurner, M.P. Fischbein, R.C. Robbins, and M.P. Pelletier. (2007). Stem cell transplantation: the lung barrier. Transplant Proc 39:573-576
33. Ben-Mordechai T, R. Holbova, N. Landa-Rouben, T. Harel-Adar, M.S. Feinberg, I. Abd Elrahman, G. Blum, F.H. Epstein, Z. Silman, S. Cohen, and J. Leor. (2013). Macrophage subpopulations are essential for infarct repair with, and without stem cell therapy. J Am Coll Cardiol 62:1890-1901
34. Hoogduijn MJ, M. Roemeling-van Rhijn, A.U. Engela, S.S. Korevaar, F.K. Mensah, M. Franquesa, RW de Bruin, M.G. Betjes, W. Weimar, and C.C. Baan. (2013). Mesenchymal stem cells induce an inflammatory response after intravenous infusion. Stem Cells Dev 22:2825-2835
35. Roemeling-van Rhijn M, M.E. Reinders, A de Klein, H. Douben, S.S. Korevaar, F.K. Mensah, F.J. Dor, JN IJzermans, M.G. Betjes, et al. (2012). Mesenchymal stem cells derived from adipose tissue are not affected by renal disease. Kidney Int 82:748-758
36. Hoogduijn MJ, M.J. Crop, A.M. Peeters, G.J. Van Osch, A.H. Balk, J.N. Ijzermans, W. Weimar, and C.C. Baan. (2007). Human heart, spleen, and perirenal fat-derived mesenchymal stem cells have immunomodulatory capacities. Stem Cells Dev 16:597-604
37. Soleimani M, and S. Nadri. (2009). A protocol for isolation, and culture of mesenchymal stem cells from mouse bone marrow. Nat Protoc 4:102-106
38. Mitchell JR, M. Verweij, K. Brand, M van de Ven, N. Goemaere, S van den Engel, T. Chu, F. Forrer, C. Muller, et al. (2010). Short-Term dietary restriction, and fasting precondition against ischemia reperfusion injury in mice. Aging Cell 9:40-53
39. Franquesa M, F.K. Mensah, R. Huizinga, T. Strini, L. Boon, E. Lombardo, O. DelaRosa, J.D. Laman, J.M. Grinyo, et al. (2015). Human adipose tissue-derived mesenchymal stem cells abrogate plasmablast formation, and induce regulatory B cells independently of T helper cells. Stem Cells 33:880-891
40. Yang SH, M.J. Park, I.H. Yoon, S.Y. Kim, S.H. Hong, J.Y. Shin, H.Y. Nam, Y.H. Kim, B. Kim, and C.G. Park. (2009). Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10. Exp Mol Med 41:315-324
41. Gnecchi M, H. He, N. Noiseux, O.D. Liang, L. Zhang, F. Morello, H. Mu, L.G. Melo, R.E. Pratt, J.S. Ingwall, and V.J. Dzau. (2006). Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection, and functional improvement. FASEB J 20:661-669
42. Bi B, R. Schmitt, M. Israilova, H. Nishio, and L.G. Cantley. (2007). Stromal cells protect against acute tubular injury via an endocrine effect. J Am Soc Nephrol 18:2486-2496
43. Lu W, C. Fu, L. Song, Y. Yao, X. Zhang, Z. Chen, Y. Li, G. Ma, and C. Shen. (2013). Exposure to supernatants of macrophages that phagocytized dead mesenchymal stem cells improves hypoxic cardiomyocytes survival. Int J Cardiol 165:333-340
44. Nemeth K, A. Leelahavanichkul, P.S. Yuen, B. Mayer, A. Parmelee, K. Doi, P.G. Robey, K. Leelahavanichkul, B.H. Koller, et al. (2009). Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. NatMed 15:42-49
45. Liu XB, H. Chen, H.Q. Chen, M.F. Zhu, X.Y. Hu, Y.P. Wang, Z. Jiang, Y.C. Xu, M.X. Xiang, and J.A. Wang. (2012).Angiopoietin-1 preconditioning enhances survival, and functional recovery of mesenchymal stem cell transplantation. J Zhejiang Univ Sci B 13:616-623